Given these advantages, it is hard to believe that rare diseases won’t take up a bigger proportion of biopharma R&D dollars in the future.
Rare Disease R&D Investments Likely To Grow In Biopharma
Given these advantages, it is hard to believe that rare diseases won’t take up a bigger proportion of biopharma R&D dollars in the future.